

# Daniel Rea

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1101447/publications.pdf>

Version: 2024-02-01

7  
papers

332  
citations

1478505

6  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

602  
citing authors

#	ARTICLE	IF	CITATIONS
1	Six versus 12 monthsâ€™™ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technology Assessment, 2020, 24, 1-190.	2.8	11
2	Valuing preferences for treating screen detected ductal carcinoma in situ. European Journal of Cancer, 2019, 123, 130-137.	2.8	10
3	Valuing the health states associated with breast cancer screening programmes: A systematic review of economic measures. Social Science and Medicine, 2019, 228, 142-154.	3.8	13
4	Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial. Annals of Surgical Oncology, 2017, 24, 566-567.	1.5	9
5	Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTemis trial.. Journal of Clinical Oncology, 2016, 34, 1014-1014.	1.6	3
6	Addressing overtreatment of screen detected DCIS; the LORIS trial. European Journal of Cancer, 2015, 51, 2296-2303.	2.8	266
7	Low grade Ductal Carcinoma in situ (DCIS): How best to describe it?. Breast, 2014, 23, 693-696.	2.2	20